1|0|Public
50|$|The {{first of}} these drugs to be marketed was the kallikrein {{inhibitor}} ecallantide, used {{for the treatment of}} hereditary angioedema. It was approved in the United States in 2009. Another example is <b>depelestat,</b> an inhibitor of neutrophil elastase that has undergone Phase II clinical trials for the treatment of acute respiratory distress syndrome in 2006/2007 and has also been described as a potential inhalable cystic fibrosis treatment.|$|E

